The current translational data analysis, which suggested that patients with melanoma whose disease had progressed on prior ICI treatment had reduced observed TIM-3 levels, contributes to emerging evidence that, due to adaptive resistance, expression of TIM-3 is upregulated in anti–PD-(L)1–resistant tumors (41–43). The gene discussed is HAVCR2; the disease is melanoma.